Rasha Cosman, BSc, MBBS, FRACP, discusses the mechanism of action and potential role for the in vivo mRNA CAR therapy MT-302 in TROP-2–expressing epithelial cancers.
Rasha Cosman, BSc, MBBS, FRACP
Advertisement
Articles by Rasha Cosman, BSc, MBBS, FRACP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Pumitamig Plus Chemo Demonstrates Encouraging Efficacy in Frontline NSCLC
2
Oral Administration Afforded by CDK2 Inhibitors May Ease the Price of Admission in Platinum-Resistant Ovarian Cancer
3
MAIC Shows Improved PFS With Zanubrutinib Over Ibrutinib in Treatment-Naive CLL
4
Iza-Bren Improves Survival in Unresectable, Locally Advanced or Metastatic TNBC
5